Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2024-01-01
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Photodynamic Therapy for Cervical and Vaginal Intraepithelial Neoplasia
NCT06982976
Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia
NCT02304770
Multicenter Prospective Non-randomized Controlled Study of Ella Photodynamic Therapy for Cervical HSIL/CIN2
NCT07306260
Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection
NCT07059819
Research of Laser Ablation for the Treatment of Lower Anogenital Tracts' Precancerous Lesions
NCT05170620
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALA-PDT
Patients choose PDT to treat the disease
ALA-PDT
use ALA\_PDT to treat the disease
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALA-PDT
use ALA\_PDT to treat the disease
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 1 2 transformation area, colposcopy was sufficient
* the lesion boundary was completely visible
* The ECC did not indicate high-grade lesions
Exclusion Criteria
* TCT HSIL
* involving glands
* Porphyria patients, or suspected allergic to red and blue light.
* severe medical comorbiditiesï¼›
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qin Han
Role: STUDY_CHAIR
Peking Unniversity Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Unniversity Third Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022YFB3604704
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
PDT-CIN3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.